For the millions of people living with alopecia universalis — the complete loss of all body hair — the past few years have delivered something that was previously unthinkable: actual, FDA-approved treatments. Three JAK inhibitor drugs are now available by prescription, starting with Olumiant (baricitinib), which became the first systemic medicine ever approved for severe alopecia areata in June 2022. Since then, Litfulo (ritlecitinib) followed in June 2023, and the newest option, Leqselvi (deuruxolitinib), received FDA approval in July 2024. These oral medications work by blocking the immune signaling pathways that mistakenly attack hair follicles, and while they are not cures, they represent a genuine turning point for a condition that doctors could previously only address with off-label therapies and wishful thinking. The reality, though, is more complicated than headlines suggest.
Patients with alopecia universalis — the most severe end of the spectrum — tend to respond at lower rates and more slowly than those with patchy hair loss. In one real-world study of baricitinib, only two out of six AU patients reached clinically meaningful improvement, and none achieved complete regrowth. That is not a reason to lose hope, but it is a reason to approach these treatments with clear expectations. These drugs help a meaningful percentage of people, but they do not help everyone, and they require ongoing use. This article breaks down what each of the three approved drugs actually does, how they compare, what they cost, who can access them, and what the emerging science says about treatments still in development. If you or someone you care for is dealing with total hair loss, the landscape has genuinely changed — but the details matter.
Table of Contents
- What Are the New Drugs for Alopecia Universalis, and How Do They Work?
- How Effective Are JAK Inhibitors Specifically for Total Hair Loss?
- Comparing the Three Approved Treatments — Olumiant, Litfulo, and Leqselvi
- What Does Treatment Actually Cost, and Can You Get It Covered?
- Side Effects, Risks, and Who Should Think Twice
- The Emotional Weight of Alopecia Universalis and Why Treatment Access Matters
- What Is Coming Next — Emerging Therapies Beyond JAK Inhibitors
- Conclusion
- Frequently Asked Questions
What Are the New Drugs for Alopecia Universalis, and How Do They Work?
All three FDA-approved treatments belong to a class of medications called JAK inhibitors, which target the Janus kinase enzymes involved in the inflammatory immune response that destroys hair follicles. Olumiant (baricitinib), made by Eli Lilly and Incyte, was the trailblazer — approved in June 2022 as a once-daily oral pill for adults 18 and older. In clinical trials, 32 to 35 percent of patients with extensive hair loss who took the 4 mg dose achieved at least 80 percent scalp hair coverage after 36 weeks. For a condition that had zero approved systemic treatments before that date, those numbers were groundbreaking. Pfizer’s Litfulo (ritlecitinib) arrived a year later and broke new ground of its own: it was approved for patients aged 12 and older, making it the first treatment option for adolescents with severe alopecia areata. At the 50 mg dose, 23 percent of patients hit the same benchmark of 80 percent or greater coverage at 24 weeks, compared to just 2 percent on placebo. The newest entrant, Leqselvi (deuruxolitinib) from Sun Pharma, earned its FDA approval in July 2024 and became commercially available in the United States in July 2025.
Its mechanism is similar to baricitinib — both are JAK1/JAK2 inhibitors — but Leqselvi is taken twice daily rather than once. In the THRIVE-AA1 trial, approximately 29.6 percent of patients on the 8 mg twice-daily dose achieved 80 percent or greater scalp hair regrowth at 24 weeks, and about 23 percent reached 90 percent or greater regrowth. The long-term data is particularly encouraging: by week 68 in pooled open-label extensions, 48.8 percent of patients achieved a SALT score of 20 or below, meaning near-complete regrowth. What separates these drugs from older alopecia treatments is specificity. Previous options like corticosteroids or immunosuppressants cast a wide net over the immune system, often with significant side effects and inconsistent results. JAK inhibitors are more targeted, though they are not without their own risks. Each drug carries a distinct side effect profile — Leqselvi’s most common issues include headache (12.4 percent of patients), acne (10 percent), nasopharyngitis (8.1 percent), and elevated creatine phosphokinase (5.3 percent). These are medications that require monitoring and a conversation with a dermatologist, not decisions to make from a headline.
How Effective Are JAK Inhibitors Specifically for Total Hair Loss?
Here is where honest expectations become critical. The clinical trial numbers cited above come from studies that included patients across the severity spectrum of alopecia areata — from those who had lost 50 percent of their scalp hair to those with alopecia universalis who had lost every hair on their body. When you isolate the AU population specifically, the response rates are lower and the timeline is longer. Ritlecitinib’s trial data did show statistically significant improvement over placebo even in the AU and alopecia totalis subgroup, which is meaningful. But “statistically significant” and “my hair grew back” are not always the same thing for an individual patient. A real-world follow-up study of baricitinib tracked six patients with alopecia universalis over the course of a year. Of those six, two — 33.3 percent — reached a clinically meaningful improvement defined as a SALT score of 20 or below. However, none of the six achieved complete regrowth.
This is a small sample, and real-world studies have inherent limitations, but it aligns with the broader pattern that clinicians observe: the more extensive the hair loss and the longer it has persisted, the harder it is to reverse. Hair regrowth in responsive patients typically begins within 4 to 16 weeks of starting treatment, with a median of roughly 8.5 months for those who do achieve substantial regrowth. The critical caveat that every patient with AU needs to hear is this: these are not cures. They are ongoing treatments. When patients stop taking JAK inhibitors, the immune attack on hair follicles can resume, and hair loss often returns. This means committing to daily medication for an indefinite period, with the costs, side effects, and medical monitoring that entails. For some patients, that tradeoff is absolutely worth it. For others — particularly those who have adapted well to hair loss or who have contraindications — it may not be. A dermatologist experienced with these medications is the right person to help weigh those factors.
Comparing the Three Approved Treatments — Olumiant, Litfulo, and Leqselvi
Choosing among these three drugs is not simply a matter of picking the newest one. Each has characteristics that may make it a better or worse fit depending on the patient’s age, medical history, and tolerance for various side effects. Olumiant has the longest track record since its 2022 approval and the most accumulated real-world data. It also has promising pediatric data: the Phase 3 BRAVE-AA-PEDS trial showed near-complete scalp hair regrowth at one year in adolescents, though it remains officially approved only for adults 18 and older for this indication. Litfulo is the clear choice for the 12-to-17 age group, as it is the only JAK inhibitor currently approved for adolescents with severe alopecia areata. Leqselvi distinguishes itself with strong long-term efficacy data.
That 48.8 percent SALT-20 response rate at week 68 is notable — and when researchers looked at the observed data analysis, which accounts for patients who stayed on the drug, the number climbed to 76.6 percent. Its clinical trials involved more than 1,200 patients with 50 percent or greater scalp hair loss, making it one of the larger datasets in this space. The twice-daily dosing is a practical consideration, though. For someone who struggles with medication adherence, a once-daily pill like Olumiant or Litfulo may be a more realistic choice. Litfulo also uses a somewhat different mechanism — it inhibits JAK3 and TEC family kinases rather than JAK1/JAK2 — which means that a patient who does not respond to one drug may still respond to another. In practice, dermatologists often start with whichever drug they can get covered by a patient’s insurance, then reassess after several months. Switching between JAK inhibitors when the first choice does not produce adequate results is becoming a more common part of the treatment conversation, and having three approved options rather than one gives clinicians meaningful flexibility.
What Does Treatment Actually Cost, and Can You Get It Covered?
The sticker price for these medications is steep. Without insurance or patient assistance programs, the monthly out-of-pocket cost for JAK inhibitors used in alopecia areata runs between $2,898 and $4,348 in the United States. That translates to roughly $35,000 to $52,000 per year — an amount that puts these drugs out of reach for most people without some form of coverage. Insurance coverage exists but remains frustratingly inconsistent. A 2025 analysis presented at the American Academy of Dermatology found that only 52.9 percent of Medicaid plans covered both Olumiant and Litfulo, while 15.7 percent covered only Olumiant. That means a substantial portion of Medicaid beneficiaries have limited or no formulary access to these treatments.
For patients with commercial insurance, prior authorization is almost always required, specialty pharmacy fulfillment is standard, and initial denials are common. Many patients and their dermatologists end up going through appeals processes — sometimes multiple rounds — before securing approval. Both Eli Lilly and Pfizer offer bridge programs designed for commercially insured patients who are experiencing coverage delays or denials. These programs can provide temporary access to medication while the insurance process plays out. The National Alopecia Areata Foundation also maintains resources to help patients navigate insurance barriers. If cost is a concern — and for most people it will be — raising it directly with your dermatologist early in the conversation is important. They can often identify the path of least resistance for coverage before writing the first prescription.
Side Effects, Risks, and Who Should Think Twice
JAK inhibitors are immunomodulatory drugs, and that comes with genuine risk considerations. The FDA has placed boxed warnings on JAK inhibitors as a class, based partly on safety data from their use in rheumatoid arthritis, noting potential risks including serious infections, cardiovascular events, malignancy, and thrombosis. In the alopecia areata population — which tends to be younger and healthier than the rheumatoid arthritis population — these risks appear lower, but they are not zero, and long-term safety data specific to alopecia patients is still accumulating. For Leqselvi specifically, the most commonly reported side effects in clinical trials were headache (affecting 12.4 percent of patients), acne (10 percent), nasopharyngitis (8.1 percent), and elevated creatine phosphokinase levels (5.3 percent).
The acne finding is worth noting because it can be particularly frustrating for patients who are already dealing with a visible condition. Blood work monitoring is typically required at baseline and periodically during treatment to watch for changes in blood counts, liver function, and lipid levels. Patients who have a history of serious infections, active tuberculosis, or severe liver impairment are generally not candidates for these medications. People over 65, heavy smokers, and those with a history of cardiovascular disease or cancer need a particularly careful risk-benefit discussion. And because these drugs suppress part of the immune system, patients on JAK inhibitors need to stay current on vaccinations — ideally completing any live vaccines before starting treatment, since live vaccines are contraindicated during use.
The Emotional Weight of Alopecia Universalis and Why Treatment Access Matters
Alopecia universalis is not just hair loss. It is the loss of eyebrows, eyelashes, nasal hair, and every other hair on the body, each of which serves both functional and social roles. The psychological burden is well documented: higher rates of anxiety, depression, social withdrawal, and reduced quality of life compared to the general population. For adolescents in particular — a group now reachable through Litfulo’s approval for ages 12 and up — the timing of hair loss during identity formation can have lasting effects on self-image and social development.
This is why the access and cost barriers are not merely financial inconveniences. When a drug exists that could restore hair for a teenager who has withdrawn from school activities, and the obstacle is a prior authorization denial or a Medicaid formulary gap, the system is failing in a way that has human consequences. Patient advocacy organizations, particularly the National Alopecia Areata Foundation, have been vocal about pushing for broader coverage, and dermatologists are increasingly trained to fight insurance battles on behalf of their patients. But the burden still falls disproportionately on patients and families.
What Is Coming Next — Emerging Therapies Beyond JAK Inhibitors
JAK inhibitors are the present, but they may not be the final chapter. As of 2026, several early-stage clinical trials are exploring fundamentally different approaches. Lab-grown follicle cell injections aim to regenerate hair by transplanting cultured dermal papilla cells directly into the scalp — essentially growing new follicles rather than trying to rescue damaged ones. Stem cell reprogramming research seeks to convert other cell types into follicle-generating cells, which could eventually offer a one-time procedure rather than ongoing medication.
Exosome therapy, which uses cell-derived signaling vesicles to modulate the local immune environment around follicles, is another avenue under active investigation. All of these are in early stages, and none is likely to reach patients within the next two to three years. But they represent a shift in thinking — from suppressing the immune attack to rebuilding what was lost or fundamentally reprogramming the immune environment. For patients who do not respond to JAK inhibitors or who cannot tolerate them, these emerging approaches may eventually provide alternatives. In the meantime, the three approved JAK inhibitors remain the most evidence-backed options available, and the data on their long-term effectiveness continues to grow.
Conclusion
After decades with no approved treatments, people with alopecia universalis now have three FDA-approved JAK inhibitors to discuss with their doctors: Olumiant, Litfulo, and Leqselvi. The efficacy data is real — these drugs produce meaningful hair regrowth for a significant percentage of patients — but so are the limitations. Response rates are lower for total hair loss than for patchy forms, the drugs require ongoing use, and cost and insurance barriers remain substantial obstacles for many people.
The most important step for anyone considering these treatments is a frank conversation with a dermatologist who has experience prescribing JAK inhibitors for alopecia. Bring your questions about efficacy expectations for your specific severity, the side effect profile, the insurance landscape, and what monitoring will be required. These drugs are not magic, but they are genuine medicine for a condition that went untreated for far too long. That is progress worth understanding clearly.
Frequently Asked Questions
Can JAK inhibitors completely cure alopecia universalis?
No. JAK inhibitors are ongoing treatments, not cures. They work by suppressing the immune attack on hair follicles, but when the medication is stopped, the immune response can resume and hair loss often returns. Patients should expect to remain on the drug indefinitely to maintain results.
How long does it take to see hair regrowth on a JAK inhibitor?
Most responsive patients begin seeing regrowth within 4 to 16 weeks of starting treatment. However, the median time to achieve substantial regrowth is approximately 8.5 months. Patients with alopecia universalis may take longer than those with less extensive hair loss.
Which JAK inhibitor is available for teenagers?
Litfulo (ritlecitinib) is the only JAK inhibitor currently approved for patients aged 12 and older. Olumiant and Leqselvi are approved only for adults 18 and over, though Olumiant has shown promising results in a Phase 3 adolescent trial.
What if my insurance denies coverage for a JAK inhibitor?
Denials are common and often require appeals. Both Eli Lilly (for Olumiant) and Pfizer (for Litfulo) offer bridge programs for commercially insured patients facing coverage delays. Your dermatologist’s office can typically assist with the appeals process and help identify which drug is most likely to be covered by your specific plan.
Are the side effects of JAK inhibitors dangerous?
Most common side effects — headache, acne, nasopharyngitis — are mild to moderate. However, JAK inhibitors carry a class-wide boxed warning for potential serious risks including infections, cardiovascular events, malignancy, and blood clots. These risks appear lower in the younger, healthier alopecia population than in rheumatoid arthritis patients, but regular monitoring through blood work is required.
Do JAK inhibitors regrow eyebrows and body hair, or only scalp hair?
Clinical trials primarily measured scalp hair regrowth, but many patients report regrowth of eyebrows, eyelashes, and body hair as well. Results vary by individual, and body hair regrowth may follow a different timeline than scalp hair.
